HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Seeks Input On Cosmetics GMP Development, Industry Costs, Likely Safety Impacts

Executive Summary

The agency is accepting comments from 27 April to 3 July 2023 to Docket No. FDA-2023-N-1466 to inform its development of good manufacturing practices for facilities that manufacture or process cosmetic products distributed in the United States. A virtual “listening session” is slated for 1 June.

You may also be interested in...

Lauder In-House Counsel: Start Planning For Supply Chain Quality Agreements Under MoCRA

Companies that have struggled to secure quality agreements with suppliers have additional leverage and a new starting point for those discussions, namely the Modernization of Cosmetic Regulations Act. Anand Natarajan, associate counsel at The Estee Lauder Companies, provided his view in a recent FDLI webinar.

FDA’s Linda Katz Addresses Why VCRP Wouldn’t Work For Cosmetics Registration Under MoCRA

The cosmetics office director assured attendees of a 27 April FDLI webinar that the agency’s launch of a new platform for cosmetics registration and product listing will afford companies sufficient time to comply with new requirements under the Modernization of Cosmetic Regulations Act.

MoCRA Check-In: FDA Guidance Urgently Needed As Year-End Compliance Deadlines Loom

John Bailey, independent advisor for colors and cosmetics at EAS Consulting Group, is checking in with HBW Insight periodically in 2023 to offer his views on developments under the US Modernization of Cosmetic Regulations Act of 2022. Here he discusses the urgent need for FDA guidance as deadlines creep closer for registration, product listing, safety substantiation, and adverse event reporting.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts